Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …
B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free
survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the
drug's efficacy in advanced non–small cell lung cancer (NSCLC). Objective To investigate
the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing
after second-line or further treatment. Design, Setting, and Participants The ALTER 0303 trial …
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free
survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the
drug's efficacy in advanced non–small cell lung cancer (NSCLC). Objective To investigate
the efficacy of anlotinib on overall survival of patients with advanced NSCLC progressing
after second-line or further treatment. Design, Setting, and Participants The ALTER 0303 trial …
以上显示的是最相近的搜索结果。 查看全部搜索结果